Saturday, 31 October 2026European Markets

ELECTROMAGNET GEO Stock Impressive Jump On Wednesday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with ELECTROMAGNET GEO (EMGS.OL) jumping 10.02% to kr2.25 on Wednesday while Oslo Børs Benchmark Index_GI rose 0.91% to kr1,437.67.

ELECTROMAGNET GEO's last close was kr2.05, 52.22% under its 52-week high of kr4.28.

About ELECTROMAGNET GEO

Electromagnetic Geoservices ASA, together with its subsidiaries, provides electromagnetic (EM) surveying technology and services to the offshore oil and gas exploration industry. It is involved in the planning, acquisition, processing, modelling, interpretation, and integration of EM data. The company also uses its patented EM survey method to find hydrocarbons in offshore reservoirs. In addition, it engages in the provision of controlled-source EM surveying and magnetotelluric surveying; imaging and interpretation; rental of software and cluster; and training services. The company has operations in Europe, the Middle East, Africa, Norway, North and South America, Asia, and the Pacific Ocean. Electromagnetic Geoservices ASA was incorporated in 2002 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ELECTROMAGNET GEO has a trailing twelve months EPS of kr-0.84.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 145.52%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

ELECTROMAGNET GEO's EBITDA is 15.12.

Volatility

ELECTROMAGNET GEO's last week, last month's, and last quarter's current intraday variation average was a negative 1.33%, a negative 0.57%, and a positive 2.68%.

ELECTROMAGNET GEO's highest amplitude of average volatility was 1.93% (last week), 2.65% (last month), and 2.68% (last quarter).

More news about ELECTROMAGNET GEO (EMGS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,514 source documents archived
Query this data → isubstrate.com